107. Juvenile idiopathic arthritis Clinical trials / Disease details

Clinical trials : 447 / Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-003260-20-NL (EUCTR)	04/05/2016	17/11/2015	CHAMP Trial: comparing monotherapy and polytherapy treatment strategies in newly diagnosed juvenile idiopathic arthritis.	CHAMP: Children with Arthritis: Monotherapy or Polytherapy. A multicentre, single-blinded, randomized treat to target, one-year follow-up clinical trial in patients with recent onset Juvenile Idiopathic Arthritis (JIA). - CHAMP	Juvenile idiopathic arthritis;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: Methotrexate INN or Proposed INN: METHOTREXATE Other descriptive name: METHOTREXATE Trade Name: sulfasalazine Product Name: Sulfasalazine INN or Proposed INN: SULFASALAZINE Other descriptive name: SULFASALAZINE Trade Name: Hydroxychloroquine Product Name: Hydroxychloroquine INN or Proposed INN: HYDROXYCHLOROQUINE Other descriptive name: HYDROXYCHLOROQUINE	Leiden University Medical Centre	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	130	Phase 4	Netherlands
2	NCT00637780 (ClinicalTrials.gov)	June 2010	11/3/2008	Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis	An Open Label Non-randomized Study To Characterize The Steady State Pharmacokinetics Of Sulfasalazine Delayed Release Tablets In Children With Juvenile Idiopathic Arthritis	Arthritis, Juvenile Rheumatoid	Drug: Sulfasalazine	Pfizer	NULL	Terminated	6 Years	17 Years	All	2	Phase 4	United States;Mexico;Canada